



**Clearbridge Health Limited**  
37 Jalan Pemimpin #08-05 Mapex Singapore 577177  
TEL 65 6251 0136 FAX 65 6251 0132  
clearbridgehealth.com

## Clearbridge's associate completes fund raising exercise; appoints advisors for potential IPO

- *New monies of S\$6.6 million raised will be deployed to develop clinical laboratory tests and to finance the potential IPO of Clearbridge BioMedics Pte. Ltd.*
- *In conjunction with the fund raising exercise and in preparation for the potential IPO, all existing preferred shares and convertible securities were converted into ordinary shares*

**SINGAPORE – 19 July 2018 – Clearbridge Health Limited** (“Clearbridge” or the “Company” and together with its subsidiaries, the “Group”) (明策集团) said its associated company, Clearbridge BioMedics Pte. Ltd. (“Clearbridge BioMedics”) has completed its fund raising exercise and the new monies raised of S\$6.6 million will be deployed to establish Laboratory Developed Tests (“LDTs”) using Clearbridge BioMedics’ technology for clinical applications as well as to finance the potential initial public offering (“IPO”) of Clearbridge BioMedics.

In conjunction with the fund raising exercise and to simplify the capital structure of Clearbridge BioMedics, all preferred shares and convertible securities were converted to ordinary shares in Clearbridge BioMedics. Following the completion of the fund raising exercise and the conversion of preferred shares and convertible securities, the Company’s shareholding interest in Clearbridge BioMedics, which is held through its wholly-owned subsidiary, Clearbridge BSA Pte. Ltd., has decreased from 39.7% to 31.3%.

**Mr Jeremy Yee (余斌), Executive Director and Chief Executive Officer of Clearbridge**, said: *“We had made it clear since our Group’s IPO that we planned to expand our internal capabilities in laboratory testing as well as to enhance our delivery and promotion of precision medicine in the region. We had also consistently reiterated that we were focused on value creation for our shareholders through the potential monetisation of certain assets. In this regard, Clearbridge BioMedics has appointed professional parties to advise on its potential IPO. We are very encouraged that the recent developments at Clearbridge BioMedics have enabled us to fulfil these twin objectives.”*

Clearbridge BioMedics is a specialist in non-invasive liquid biopsy for real time analysis of cancer cells from a standard blood draw and has developed the ClearCell<sup>®</sup> FX System, one of the world’s first fully automated cell retrieval systems that is now distributed via a network of 12 distributors across the EMEA and APAC regions. The ClearCell<sup>®</sup> FX System has attained various regulatory registrations, such as Europe’s CE IVD certification, USA’s FDA, and China’s CFDA via a Chinese partner. This groundbreaking system provides healthcare professionals with vital and accurate information that allows them to deliver targeted healthcare treatment to patients. In addition to providing clinical benefits, Clearbridge BioMedics’s cancer diagnostics solutions help to lower patients’ medical costs and reduce the inconveniences they encounter.



**Clearbridge Health Limited**  
37 Jalan Pemimpin #08-05 Mapex Singapore 577177  
TEL 65 6251 0136 FAX 65 6251 0132  
clearbridgehealth.com

Highlighting the prospects of the precision medicine industry, Mr Yee said that the individualised approach to the diagnosis and treatment of diseases such as cancer and diabetes has given patients renewed hope for better outcomes. He said: *“Precision medicine helps to ensure that patients avoid having to suffer a battery of ineffective drugs and treatment options. There is increasing awareness about the benefits and effectiveness of precision medicine and this has led to tremendous growth potential for companies such as Clearbridge BioMedics. By leveraging on LDTs and medical technology, Clearbridge BioMedics enables healthcare professionals to identify the genetic make-up of individual patients so that they can be matched with specific drugs and treatment programmes that are tailored for them. We believe that there is a real need for the healthcare solutions that Clearbridge BioMedics offers.”*

-- END --

*This press release should be read in conjunction with Clearbridge’s announcement released via SGXNet on 19 July 2018.*

#### **About Clearbridge Health Limited**

Clearbridge Health Limited is a healthcare company which focuses on delivering precision medicine in Asia. Its business comprises laboratory testing services, medical clinics/centres and strategic equity participation in complementary precision medical technology companies. Through the delivery of precision medicine in Asia, it seeks to empower clinicians and healthcare professionals to make more reliable and accurate diagnoses, provide insights on disease management, and tailor personalised prevention and timely treatment programmes for patients.

For more information, please visit us at [www.clearbridgehealth.com](http://www.clearbridgehealth.com).

#### **About Clearbridge BioMedics Pte Ltd**

Clearbridge BioMedics Pte Ltd. is a clinical stage cancer diagnostics company that develops and manufactures liquid biopsy systems. Clearbridge BioMedics is based in Singapore and has commercially launched the ClearCell® FX platform to laboratories around the globe. Clearbridge BioMedics has won numerous awards and garnered global recognition for its novel Circulating Tumor Cell (CTC) detection platform technology, the ClearCell® FX System. The ClearCell® FX System and its biochip are utilizing state-of-the-art, non-invasive liquid biopsy to analyze blood samples for circulating tumor cells (CTCs). The device allows for real time analysis of disease before, during, and after treatment, which has become increasingly critical in the new era of targeted cancer therapies.

Clearbridge BioMedics has received ISO 13485 certification in 2011 and the ClearCell® FX System attained CE IVD in 2015 and US FDA Class 1 registration in 2017. In China, the same system is available as China FDA approved Class 1 system as the EasyCell system, through a partnership with MGI (an associate of Beijing Genomics Institute (BGI)).

For more information, visit [www.ClearbridgeBioMedics.com](http://www.ClearbridgeBioMedics.com).



**Clearbridge Health Limited**  
37 Jalan Pemimpin #08-05 Mapex Singapore 577177  
TEL 65 6251 0136 FAX 65 6251 0132  
clearbridgehealth.com

---

*Issued by and on behalf of Clearbridge Health Limited*

**August Consulting**

Tel: +65 6733 8873

Silvia Heng, [silviaheng@august.com.sg](mailto:silviaheng@august.com.sg)

Wrisney Tan, [wrisneytan@august.com.sg](mailto:wrisneytan@august.com.sg)

Zavier Ong, [zavierong@august.com.sg](mailto:zavierong@august.com.sg)

*This press release has been prepared by the Company and its contents have been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "SGX-ST").*

*The Sponsor has not independently verified the contents of this press release. This press release has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.*

*The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*